NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=124866&from=4CLASS PERIOD: T ...

SAN DIEGO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. For mo ...

Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's February 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Kyverna Therapeutics, Inc. [2] - The complaint alleges that false statements and omissions were made regarding the IPO strategy, terms, and disclosures in the Offering Documents [3]. - The underwriter defendants are accused of being aware of Kyverna's undisclosed issues due to constant communications with the company's management and legal representatives [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 7, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities investing Kyverna common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 8, 2024 (the "IPO" or "Offering") and would like to discuss your legal rights, call Faruqi & Faruqi partner ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Developmen ...

Core Viewpoint - Kyverna Therapeutics, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Company Summary - The lawsuit is being pursued by Levi & Korsinsky, and affected parties are encouraged to contact the firm before February 7, 2025, to discuss their rights [1]

Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX ...

Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...